Wells Fargo
BCAX

Wells Fargo’s Bicara Therapeutics BCAX Stock Holding History

Wells Fargo’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Buy
39,893
+24,916
+166% +$556K ﹤0.01% 3985
2026
Q1 		$298K Sell
14,977
-20,266
-58% -$349K ﹤0.01% 4456
2025
Q4 		$593K Buy
35,243
+9,319
+36% +$159K ﹤0.01% 4362
2025
Q3 		$409K Buy
25,924
+4,223
+19% +$47.3K ﹤0.01% 4450
2025
Q2 		$202K Buy
21,701
+11,448
+112% +$136K ﹤0.01% 4767
2025
Q1 		$134K Buy
10,253
+226
+2% +$3K ﹤0.01% 4937
2024
Q4 		$175K Buy
+10,027
New +$209K ﹤0.01% 4873

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wells Fargo's BCAX Position: Q2 2026 in Review

Wells Fargo increased its Bicara Therapeutics (BCAX) stake by 166% in Q2 2026, buying an estimated $556K and bringing the position to 39,893 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3985.

Wells Fargo first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Wells Fargo held 39,893 shares of Bicara Therapeutics worth $1.18M as of Q2 2026.
  • Wells Fargo bought 24,916 Bicara Therapeutics shares in Q2 2026, an estimated $556K.
  • Bicara Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3985 holding.
  • Wells Fargo first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.